첫 페이지 News 본문

Japanese pharmaceutical company Kaken announced on December 26th that it has signed a license agreement with Johnson&Johnson for the global development, production, and commercialization of the STAT6 project that Kaken is currently developing. According to the terms of the agreement, Kaken will grant Johnson&Johnson an exclusive license for the global development, production, and commercialization of the STAT6 project, including KP-723 (an oral STAT6 inhibitor in preclinical development). Kaken will advance the completion of Phase I clinical trials for KP-723, after which Johnson&Johnson will conduct clinical development and commercialization worldwide. Kaken will retain its commercial rights in Japan, while Johnson&Johnson can choose to sign a joint promotion agreement with Kaken. Kaken will receive a $30 million advance payment from Johnson&Johnson. Based on development progress and sales milestones, Kaken will be eligible for successful payments of up to $1.2175 billion, as well as lower double-digit global sales royalties.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

海角七号 注册会员
  • Follow

    0

  • Following

    1

  • Articles

    29